SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aardvark Therapeutics, Inc. (AARD)

A shareholder filed a securities class action lawsuit against Aardvark Therapeutics (NASDAQ: AARD) targeting investors who bought shares via the Feb. 13, 2025 IPO and/or bought Aardvark securities during the Feb. 13, 2025–May 14, 2026 class period. The announcement signals potential legal and disclosure-risk overhang rather than any new operating or financial results. Expect a modest risk-off reaction for the stock as litigation exposure crystallizes.

Analysis

This is more of a cost-of-capital event than an operating event. For a small-cap biotech, the first-order hit is usually multiple compression and a higher discount rate on any future financing, not an immediate change in intrinsic value — unless the complaint points to a core disclosure problem tied to clinical data or cash runway. That distinction matters because a garden-variety securities suit tends to damage sentiment for days, while a substantiated disclosure issue can impair access to capital for quarters.

The second-order effect is on the whole microcap biotech complex: investors often start pricing a broader “IPO paper” penalty when one name gets tagged, which can spill into peers with similar capital structures, thin liquidity, and limited sell-side coverage. If AARD still needs to raise money within 6-12 months, litigation can turn a routine follow-on into a punitive dilution event; if it is already funded, the main damage is reputational and technical, with less fundamental consequence.

Contrarianly, the market often over-discounts these announcements before the complaint is tested. Most class actions settle from insurance and don’t destroy the equity unless there is a smoking gun tied to efficacy, safety, or accounting. The thesis is falsified if the company quickly discloses a strong cash position, insurance coverage, or if the stock recovers after the initial headline fade; the bear case strengthens only if the complaint survives a motion to dismiss and the company’s next filing shows looming financing needs.

Key Decisions for Investors

• Avoid initiating a fresh short in AARD until the complaint details and borrow availability are known; this is a low-conviction event-driven setup unless the alleged misstatement is specific and material.
• If already short, use the first 1-2 day post-headline dislocation to cover 25-50% into weakness unless the filing reveals accounting or clinical-data risk; most of the easy downside tends to occur immediately.
• Watch AARD’s next 10-Q/8-K for cash runway and litigation reserves; if liquidity is <12 months, the trade shifts from sentiment short to financing-dilution short over the next 1-3 months.
• Relative-value idea: short AARD against a basket/ETF proxy such as XBI only if the event starts to spill into broader small-cap biotech multiples; otherwise the idiosyncratic move may be too small versus borrow costs.
• Set an alert for any amendment/response from the company or motion-to-dismiss timing; a quick procedural win or insurance disclosure would be the cleanest catalyst to fade the initial selloff.